Getagraph.com logo
S&P 500 Futures
(0.23%) 5 143.25 points
Dow Jones Futures
(0.20%) 38 519 points
Nasdaq Futures
(0.33%) 17 904 points
Oil
(-0.58%) $83.36
Gas
(2.03%) $1.962
Gold
(0.08%) $2 349.00
Silver
(0.28%) $27.61
Platinum
(0.78%) $929.25
USD/EUR
(-0.19%) $0.933
USD/NOK
(-0.26%) $11.00
USD/GBP
(-0.31%) $0.798
USD/RUB
(1.11%) $92.90

实时更新： Ocugen Inc [OCGN]

交易所: NASDAQ 部门: Healthcare 工业: Biotechnology
Upcoming Earnings Alert

4 days till quarter result
(bmo 2024-05-03)

Expected move: +/- 11.53%

BUY
100.00%
return 9.47%
SELL
100.00%
return -10.94%
最后更新时间27 Apr 2024 @ 04:00
25% discount on Stockinvest.us - Use code: Podcast

8.47% $ 1.280

购买 107260 min ago

@ $0.657

发出时间: 15 Feb 2024 @ 04:30

回报率: 94.97%

上一信号: Feb 14 - 22:30

上一信号: 出售

回报率: 6.16 %

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 04:00):
Profile picture for Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD...

Stats
今日成交量 5.36M
平均成交量 9.33M
市值 329.38M
EPS $0 ( 2024-04-02 )
下一个收益日期 ( $-0.0600 ) 2024-05-03
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -4.92
ATR14 $0.00800 (0.63%)
Insider Trading
Date Person Action Amount type
2024-04-16 Qamar Huma Buy 308 465 Option (Right to Buy)
2024-03-18 Qamar Huma Sell 0 Common Stock
2023-09-15 Breininger Michael Buy 0
2024-01-03 Musunuri Shankar Sell 180 204 Common Stock
2024-01-03 Upadhyay Arun Sell 41 633 Common Stock
INSIDER POWER
65.23
Last 96 transactions
Buy: 10 862 012 | Sell: 2 992 475

音量 相关性

長: -0.02 (neutral)
短: 0.14 (neutral)
Signal:(53.611) Neutral

Ocugen Inc 相关性

10 最正相关
10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Ocugen Inc 相关性 - 货币/商品

The country flag 0.00
( neutral )
The country flag 0.20
( neutral )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag -0.52
( weak negative )

Ocugen Inc 财务报表

Annual 2023
营收: $6.04M
毛利润: $5.33M (88.34 %)
EPS: $-0.260
FY 2023
营收: $6.04M
毛利润: $5.33M (88.34 %)
EPS: $-0.260
FY 2022
营收: $0
毛利润: $-1.07M (0.00 %)
EPS: $-0.360
FY 2021
营收: $0.00
毛利润: $0.00 (0.00 %)
EPS: $-0.300

Financial Reports:

No articles found.

Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.

关于 实时信号

此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟；与所有市场信号一样，存在误差或错误的可能性。

实时交易信号不是绝对的，getagraph.com 对基于这些信号采取的任何行动概不负责，如《使用条款》中所述。这些信号是基于广泛的技术分析指标。